Amphastar Pharmaceuticals, Inc.
Company Stats
- Market Cap
- $1.1B
- as of Sep 30, 2026
- Shares Outstanding
- 42.5M
- Free Float
- 74.9%
Income Statement
- Revenue
- $719.9M
- Operating Income
- $140.4M
- Net Income
- $98.1M
- EBITDA
- $172.1M
- Revenue Growth, 3Y
- 13.0%
- FCF Margin, 3Y Avg
- 21.0%
- FCF Margin, Worst Year
- 16.8%
Cash Flow
- Free Cash Flow
- $121.2M
- FCF Yield
- 11.0%
- Owner FCF Yield
- 8.6%
Balance Sheet
- Cash & Equivalents
- $170.2M
Returns & Capital
- Share Repurchases
- $75.6M
- Buyback Yield, 3Y Avg
- 6.7%
- SBC, 3Y Avg
- $24.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $719.9M | $121.2M | 16.8% |
| FY2024 | $732.0M | $172.3M | 23.5% |
| FY2023 | $644.4M | $145.3M | 22.6% |
| FY2022 | $499.0M | $65.1M | 13.1% |
| FY2021 | $437.8M | $70.5M | 16.1% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back